Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Synflorix 2-4-11 Schedule
NCT00307034Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- Jan 2007
- Modality
- Split/Subunit Vaccines
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of 10-valent pneumococcal conjugate vaccine in pneumococcal infection (2 arms), sponsored by GSK. Primary endpoint: Number of Seroprotected Subjects Against Pneumococcal Serotypes at Month 3. Started Jan 2006; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00307034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307034.